Seres Therapeutics, Inc.
MCRB
$7.84
-$0.12-1.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 448.44% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 448.44% | -- | -- | -- |
| Cost of Revenue | -14.57% | 261.40% | 238.82% | 48.52% | -21.34% |
| Gross Profit | 15.59% | -259.79% | -238.82% | -212.65% | -382.50% |
| SG&A Expenses | -26.37% | -19.42% | -22.97% | -34.40% | -36.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.89% | -19.86% | -24.01% | -40.87% | -46.93% |
| Operating Income | 22.54% | 20.13% | 24.01% | -71.54% | -18.18% |
| Income Before Tax | 104.53% | 103.72% | 60.06% | 3.06% | -25.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 104.53% | 103.72% | 60.06% | 3.06% | -25.33% |
| Earnings from Discontinued Operations | -- | -100.00% | 612.62% | 746.30% | 1,041.71% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4,088.24% | 121.17% | 153.03% | 188.23% | 100.12% |
| EBIT | 22.54% | 20.13% | 24.01% | -71.54% | -18.18% |
| EBITDA | 22.45% | 19.70% | 23.90% | -81.51% | -20.16% |
| EPS Basic | 2,944.94% | 113.11% | 147.77% | 176.83% | 99.85% |
| Normalized Basic EPS | 40.98% | 67.67% | 44.26% | -35.76% | 8.70% |
| EPS Diluted | 2,000.25% | 112.77% | 147.66% | 175.96% | 99.78% |
| Normalized Diluted EPS | 41.02% | 67.70% | 44.28% | -33.93% | 9.39% |
| Average Basic Shares Outstanding | 14.02% | 19.82% | 21.02% | 22.04% | 21.40% |
| Average Diluted Shares Outstanding | 14.10% | 19.91% | 21.06% | 21.60% | 20.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |